AstraZeneca PLC (AZN) - Total Assets

Latest as of March 2026: GBX114.02 Billion GBX ≈ $13.87 Million USD

Based on the latest financial reports, AstraZeneca PLC (AZN) holds total assets worth GBX114.02 Billion GBX (≈ $13.87 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check AstraZeneca PLC investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

AstraZeneca PLC - Total Assets Trend (1990–2025)

This chart illustrates how AstraZeneca PLC's total assets have evolved over time, based on quarterly financial data. Explore AstraZeneca PLC long-term investment allocation to see how much of total assets are deployed in long-term investments.

AstraZeneca PLC - Asset Composition Analysis

Current Asset Composition (December 2025)

AstraZeneca PLC's total assets of GBX114.02 Billion consist of 25.2% current assets and 74.8% non-current assets.

Asset Category	Amount (GBX)	% of Total Assets
Cash & Equivalents	GBX0.00	5.0%
Accounts Receivable	GBX16.34 Billion	14.3%
Inventory	GBX6.56 Billion	5.8%
Property, Plant & Equipment	GBX0.00	0.0%
Intangible Assets	GBX37.85 Billion	33.2%
Goodwill	GBX21.24 Billion	18.6%

Asset Composition Trend (1990–2025)

This chart illustrates how AstraZeneca PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AstraZeneca PLC market cap and net worth.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: AstraZeneca PLC's current assets represent 25.2% of total assets in 2025, a decrease from 58.1% in 1990.
Cash Position: Cash and equivalents constituted 5.0% of total assets in 2025, up from 2.1% in 1990.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 1990.
Asset Diversification: The largest asset category is intangible assets at 33.2% of total assets.

AstraZeneca PLC Competitors by Total Assets

Key competitors of AstraZeneca PLC based on total assets are shown below.

Company	Country	Total Assets
AstraZeneca PLC MX:AZNN	Mexico	MX$114.07 Billion
Novartis AG MX:NVSN	Mexico	MX$118.53 Billion
Pfizer Inc SA:PFIZ34	Brazil	R$207.62 Billion
Organon & Co NYSE:OGN	USA	$13.00 Billion
Virbac SA PA:VIRP	France	€1.82 Billion
Zhejiang Int'L Group Co Ltd SHE:000411	China	CN¥17.31 Billion
Guangdong Jiaying Pharmaceutical Co Ltd SHE:002198	China	CN¥892.78 Million
Firebrick Pharma Ltd AU:FRE	Australia	AU$2.28 Million

AstraZeneca PLC - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	0.91	0.90	1.13
Quick Ratio	0.71	0.70	0.68
Cash Ratio	0.00	0.00	0.00
Working Capital	GBX-2.96 Billion	GBX-2.99 Billion	GBX3.09 Billion

AstraZeneca PLC - Advanced Valuation Insights

This section examines the relationship between AstraZeneca PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	6.09
Latest Market Cap to Assets Ratio	0.02
Asset Growth Rate (YoY)	9.6%
Total Assets	GBX114.07 Billion
Market Capitalization	$2.50 Billion USD

Valuation Analysis

Below Book Valuation: The market values AstraZeneca PLC's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: AstraZeneca PLC's assets grew by 9.6% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for AstraZeneca PLC (1990–2025)

The table below shows the annual total assets of AstraZeneca PLC from 1990 to 2025.

Year	Total Assets	Change
2025-12-31	GBX114.07 Billion ≈ $13.88 Million	+9.65%
2024-12-31	GBX104.03 Billion ≈ $12.66 Million	+2.88%
2023-12-31	GBX101.12 Billion ≈ $12.30 Million	+4.80%
2022-12-31	GBX96.48 Billion ≈ $11.74 Million	-8.43%
2021-12-31	GBX105.36 Billion ≈ $12.82 Million	+57.90%
2020-12-31	GBX66.73 Billion ≈ $8.12 Million	+8.72%
2019-12-31	GBX61.38 Billion ≈ $7.47 Million	+1.20%
2018-12-31	GBX60.65 Billion ≈ $7.38 Million	-4.27%
2017-12-31	GBX63.35 Billion ≈ $7.71 Million	+1.32%
2016-12-31	GBX62.53 Billion ≈ $7.61 Million	+4.11%
2015-12-31	GBX60.06 Billion ≈ $7.31 Million	+2.49%
2014-12-31	GBX58.59 Billion ≈ $7.13 Million	+4.82%
2013-12-31	GBX55.90 Billion ≈ $6.80 Million	+4.42%
2012-12-31	GBX53.53 Billion ≈ $6.51 Million	+1.33%
2011-12-31	GBX52.83 Billion ≈ $6.43 Million	-5.87%
2010-12-31	GBX56.13 Billion ≈ $6.83 Million	+2.20%
2009-12-31	GBX54.92 Billion ≈ $6.68 Million	+16.98%
2008-12-31	GBX46.95 Billion ≈ $5.71 Million	-2.10%
2007-12-31	GBX47.96 Billion ≈ $5.83 Million	+60.22%
2006-12-31	GBX29.93 Billion ≈ $3.64 Million	+20.50%
2005-12-31	GBX24.84 Billion ≈ $3.02 Million	-3.17%
2004-12-31	GBX25.65 Billion ≈ $3.12 Million	+8.82%
2003-12-31	GBX23.57 Billion ≈ $2.87 Million	+9.26%
2002-12-31	GBX21.58 Billion ≈ $2.63 Million	+16.65%
2001-12-31	GBX18.50 Billion ≈ $2.25 Million	+0.27%
2000-12-31	GBX18.45 Billion ≈ $2.24 Million	-6.91%
1999-12-31	GBX19.82 Billion ≈ $2.41 Million	+7.24%
1998-12-31	GBX18.48 Billion ≈ $2.25 Million	+123.11%
1997-12-31	GBX8.28 Billion ≈ $1.01 Million	-3.28%
1996-12-31	GBX8.56 Billion ≈ $1.04 Million	+8.80%
1995-12-31	GBX7.87 Billion ≈ $957.52K	+7.54%
1994-12-31	GBX7.32 Billion ≈ $890.42K	-1.43%
1993-12-31	GBX7.42 Billion ≈ $903.30K	+19.97%
1992-12-31	GBX6.19 Billion ≈ $752.91K	-2.73%
1991-12-31	GBX6.36 Billion ≈ $774.08K	+4.27%
1990-12-31	GBX6.10 Billion ≈ $742.34K	--

About AstraZeneca PLC

LSE:AZN UK Drug Manufacturers - General

Market Cap

$2.50 Billion

GBX20.52 Trillion GBX

Market Cap Rank

#5609 Global

#11 in UK

Share Price

GBX13234.00

Change (1 day)

+0.61%

52-Week Range

GBX10120.00 - GBX15542.00

All Time High

GBX15542.00